Ryvu Therapeutics Third Quarter 2024 Earnings: zł1.10 loss per share (vs zł0.79 loss in 3Q 2023)

Ryvu Therapeutics (WSE:RVU) Third Quarter 2024 Results

Key Financial Results

• Revenue: zł25.0m (up 54% from 3Q 2023).
• Net loss: zł26.6m (loss widened by 46% from 3Q 2023).
• zł1.10 loss per share (further deteriorated from zł0.79 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ryvu Therapeutics Earnings Insights

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in Poland.

The company's shares are down 4.0% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Ryvu Therapeutics has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.